Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs PauseRX

Two GLP-1 desks, one scoreboard. We put Sprout Health and PauseRX head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 121 · Grade C

PauseRX

Visit PauseRX Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 71 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make PauseRX a bad call — it's best for readers who want explicit 503a pharmacy and physician-network disclosure. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
78
Supply Reliability
82
69
Transparency
88
72
Access Breadth
92
56
Clinical Oversight
78
76
Track Record
84
73
Sprout HealthBrief Score 86 · 71PauseRX

Price, coverage & the tracker

Sprout HealthPauseRX
Brief Score86/100 (B)71/100 (C)
Semaglutide$149/mo$199/mo
Tirzepatide$199/moFrom $249/mo (starting dose, compounded)
CoverageNot disclosedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

PauseRX: New to the tracker on 1 August 2026. The published line reads $199/mo at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.